MeSH D013322 - strongyloidiasis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Arbor Pharmaceuticals | Ivermectin | Sklice | 2012-02-07 | |||
| Edenbridge Pharmaceuticals | Ivermectin | Ivermectin | 2014-10-24 | |||
| Galderma | Ivermectin | Soolantra | 2024-04-22 | 2014-12-19 | ||
| Merck & Co | Ivermectin | Stromectol | 1996-11-22 | |||
| Padagis | Ivermectin | Ivermectin | 2020-04-13 | |||
| Senores Pharmaceuticals | Ivermectin | Ivermectin | 2024-10-16 | |||
| Taro Pharmaceutical | Ivermectin | Ivermectin | 2020-05-06 | |||
| Teva | Ivermectin | Ivermectin | 2019-09-13 | |||
| Zydus Therapeutics | Ivermectin | Ivermectin | 2022-08-02 |
Clinical Trials
Historical Success Rate
Phase 1
0%0/0
Phase 2
0%0/0
Phase 3
43%3/7
Approved: 2Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use